# FDA advisers back first four of seven unapproved peptides under review for looser rules - Reuters

*Источник: Reuters*
*Дата: 2026-07-23*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQb0ZlUndIdFdiVzRZXzB1YjA1Y1dKS2MwVU16NzhReHQ0Z0tNdE1nTnBUYmd4TjBVSmFBRG4xMW9URDFxNE0tZkFuQXZTRmwwMDlad0hBckpBVDQ0cWdJcEtUOGEtMVU4SFZySnVTZDhmY0p0UDNsTzQ2ckQyZEpMSVVjakZmSzZGbGNib203T3NNYUtfZVN6dk52MmNENjdpZ1cwRlJYMGR6QUk4ZzhNbUU3ZnZaazRuY2xxNnZzd3NtYkY2X05nVA?oc=5" target="_blank">FDA advisers back first four of seven unapproved peptides under review for looser rules</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

[Оригинал](https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/)